Biotechnology Equity
Polar Capital Biotechnology
Last updated: 2026-09-02
The Verdict
Polar Capital Biotechnology charges an expense ratio of 1.61%. On a $100,000 portfolio, that's $1,610 per year in fees, and it scales with the amount invested. Supreme.PM's decoded model tracked it at 92% correlation, for a flat monthly subscription that does not change with portfolio size.
Expense Ratio
1.61%
Star Rating
4/ 5
Market Beta
0.78
Model Correlation
92%
Sharpe Ratio
0.68
Max Drawdown
34.39%
Supreme.PM Cost
Flat monthly subscription
Not a percentage of your assets
Performance
Performance comparison — 1Y: Fund 54.7% vs Model 48.4%; 3Y: Fund 113.7% vs Model 122.5%; 5Y: Fund 97.2% vs Model 114.5%.
Alpha After Fees
Supreme.PM's model achieves 92% correlation with Polar Capital Biotechnology, providing similar exposure at a flat subscription cost.
Fee Analysis
Polar Capital Biotechnology charges 1.61% of assets annually. Supreme.PM charges a flat monthly subscription instead, so its cost does not rise as a portfolio grows.
Data sources: Refinitiv Lipper, SEC EDGAR Filings, Supreme.PM Analytics
Past performance does not guarantee future results. Model returns are backtested and may not reflect actual trading conditions.
Related
Biotechnology Equity Category
Browse all Biotechnology Equity funds
Biotechnology Equity Rankings
Top-rated Biotechnology Equity funds
Our Methodology
How we decode fund strategies
Candriam Equities Biotechnology
3-star rated
AXA Framlington Biotech
1-star rated
Pictet-Biotech
3-star rated
International Biotechnology Trust
Frequently Asked Questions
What is the expense ratio of Polar Capital Biotechnology?
Polar Capital Biotechnology has an expense ratio of 1.61%, charged as a percentage of the amount invested. Supreme.PM's decoded model is offered for a flat monthly subscription instead.
How does Supreme.PM replicate Polar Capital Biotechnology?
Supreme.PM builds a transparent, rules-based model of listed securities designed to track this fund's return profile. Over the measured period it tracked the fund closely, at 92% correlation. The model is published in full, so its positions are visible rather than disclosed with a delay.
What are the risks of fund replication?
While our models aim for high correlation, they may not perfectly match the fund's returns due to timing differences in rebalancing, transaction costs, and disclosure delays. Backtested results may not reflect future performance.
Get This Strategy
Start investing with Supreme.PM's decoded model and save on fees while capturing similar returns.